Literature DB >> 19560742

Toward effective immunotherapy for the treatment of malignant brain tumors.

Duane A Mitchell1, John H Sampson.   

Abstract

The immunologic treatment of cancer has long been heralded as a targeted molecular therapeutic with the promise of eradicating tumor cells with minimal damage to surrounding normal tissues. However, a demonstrative example of the efficacy of immunotherapy in modulating cancer progression is still lacking for most human cancers. Recent breakthroughs in our understanding of the mechanisms leading to full T-cell activation, and recognition of the importance of overcoming tumor-induced immunosuppressive mechanisms, have shed new light on how to generate effective anti-tumor immune responses in humans, and sparked a renewed and enthusiastic effort to realize the full potential of cancer immunotherapy. The immunologic treatment of invasive malignant brain tumors has not escaped this re-invigorated endeavor, and promising therapies are currently under active investigation in dozens of clinical trials at several institutions worldwide. This review will focus on some of the most important breakthroughs in our understanding of how to generate potent anti-tumor immune responses, and some of the clear challenges that lie ahead in achieving effective immunotherapy for the majority of patients with malignant brain tumors. A review of immunotherapeutic strategies currently under clinical evaluation, as well as an outline of promising novel approaches on the horizon, is included to provide perspective on the active and stalwart progress toward effective immunotherapy for the treatment of malignant brain tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19560742      PMCID: PMC2763142          DOI: 10.1016/j.nurt.2009.04.003

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  174 in total

1.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas.

Authors:  N Sugawa; A J Ekstrand; C D James; V P Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.

Authors:  R L Hayes; M Koslow; E M Hiesiger; K B Hymes; H S Hochster; E J Moore; D M Pierz; D K Chen; G N Budzilovich; J Ransohoff
Journal:  Cancer       Date:  1995-09-01       Impact factor: 6.860

3.  The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas.

Authors:  D Rimoldi; P Romero; S Carrel
Journal:  Int J Cancer       Date:  1993-05-28       Impact factor: 7.396

Review 4.  Cancer genetics/epigenetics and the X chromosome: possible new links for malignant glioma pathogenesis and immune-based therapies.

Authors:  A Mintz; W Debinski
Journal:  Crit Rev Oncog       Date:  2000

5.  Immune surveillance against a solid tumor fails because of immunological ignorance.

Authors:  A F Ochsenbein; P Klenerman; U Karrer; B Ludewig; M Pericin; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

6.  Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta.

Authors:  Rajasekharan Somasundaram; Lutz Jacob; Rolf Swoboda; Laura Caputo; Hong Song; Saroj Basak; Dimitri Monos; David Peritt; Francesco Marincola; Dewei Cai; Brigitte Birebent; Ellen Bloome; Jin Kim; Klara Berencsi; Michael Mastrangelo; Dorothee Herlyn
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

7.  Immunotherapy with autologous white cell infusions ("lymphocytes") in the treatment of recurrrent glioblastoma multiforme: a preliminary report.

Authors:  H Young; A Kaplan; W Regelson
Journal:  Cancer       Date:  1977-09       Impact factor: 6.860

8.  Common neuroectodermal antigens on human melanoma, neuroblastoma, retinoblastoma, glioblastoma and fetal brain revealed by hybridoma antibodies raised against melanoma cells.

Authors:  S K Liao; B J Clarke; P C Kwong; A Brickenden; B L Gallic; P B Dent
Journal:  Eur J Immunol       Date:  1981-06       Impact factor: 5.532

9.  Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.

Authors:  D K Moscatello; M Holgado-Madruga; A K Godwin; G Ramirez; G Gunn; P W Zoltick; J A Biegel; R L Hayes; A J Wong
Journal:  Cancer Res       Date:  1995-12-01       Impact factor: 12.701

10.  Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.

Authors:  D Boczkowski; S K Nair; D Snyder; E Gilboa
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

View more
  22 in total

Review 1.  Insights into molecular therapy of glioma: current challenges and next generation blueprint.

Authors:  Y Rajesh; Ipsita Pal; Payel Banik; Sandipan Chakraborty; Sachin A Borkar; Goutam Dey; Ahona Mukherjee; Mahitosh Mandal
Journal:  Acta Pharmacol Sin       Date:  2017-03-20       Impact factor: 6.150

2.  T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.

Authors:  Simone Krebs; Kevin K H Chow; Zhongzhen Yi; Tania Rodriguez-Cruz; Meenakshi Hegde; Claudia Gerken; Nabil Ahmed; Stephen Gottschalk
Journal:  Cytotherapy       Date:  2014-05-16       Impact factor: 5.414

Review 3.  Drug or vaccine?: selecting the appropriate treatment for malignant glioma patients.

Authors:  Xue-jun Dai; Wei-jian Jiang; Wei-min Wang; Shu-jin Zhao
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

4.  Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.

Authors:  Christina D Pham; Catherine Flores; Changlin Yang; Elaine M Pinheiro; Jennifer H Yearley; Elias J Sayour; Yanxin Pei; Colin Moore; Roger E McLendon; Jianping Huang; John H Sampson; Robert Wechsler-Reya; Duane A Mitchell
Journal:  Clin Cancer Res       Date:  2015-09-24       Impact factor: 12.531

5.  Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.

Authors:  Duane A Mitchell; Elias J Sayour; Elizabeth Reap; Robert Schmittling; Gabriel DeLeon; Pamela Norberg; Annick Desjardins; Allan H Friedman; Henry S Friedman; Gary Archer; John H Sampson
Journal:  Cancer Immunol Res       Date:  2014-11-11       Impact factor: 11.151

6.  A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.

Authors:  Fabian Wolpert; Isabel Tritschler; Alexander Steinle; Michael Weller; Günter Eisele
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

7.  Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma.

Authors:  Richard G Everson; Joseph P Antonios; Dominique N Lisiero; Horacio Soto; Rudi Scharnweber; Matthew C Garrett; William H Yong; Ning Li; Gang Li; Carol A Kruse; Linda M Liau; Robert M Prins
Journal:  Neuro Oncol       Date:  2015-09-01       Impact factor: 12.300

Review 8.  Vaccine therapies for patients with glioblastoma.

Authors:  Eli T Sayegh; Taemin Oh; Shayan Fakurnejad; Orin Bloch; Andrew T Parsa
Journal:  J Neurooncol       Date:  2014-08-28       Impact factor: 4.130

9.  Interferon regulatory factor 3 alters glioma inflammatory and invasive properties.

Authors:  Leonid Tarassishin; Sunhee C Lee
Journal:  J Neurooncol       Date:  2013-03-20       Impact factor: 4.130

10.  Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer.

Authors:  Lihong Zhang; Xuejing Yang; Zhen Sun; Jiali Li; Hui Zhu; Jing Li; Yan Pang
Journal:  Oncol Lett       Date:  2016-02-24       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.